Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 _________________________________ SCHEDULE 14AINFORMATION _________________________________ Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

| Filed by the Registrant                    |     | ☒ |
| Filed by a Party other than the Registrant |     | ☐ |

Check the appropriate box:

| ☒ |     | Preliminary Proxy Statement                                                         |
| ☐ |     | Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
| ☐ |     | Definitive Proxy Statement                                                          |
| ☐ |     | Definitive Additional Materials                                                     |
| ☐ |     | Soliciting Material Pursuant to §240.14a-12                                         |

CERO THERAPEUTICS HOLDINGS, INC. (Name of Registrant as Specified in its Charter) ____________________________________________________________________________________________________ (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ |     | No fee required.                                                                                     |
| ☐ |     | Fee paid previously with preliminary materials.                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION CERO THERAPEUTICS HOLDINGS, INC.
201 Haskins Way, Suite 230
South San Francisco, CA 94080 2025 SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON , 2025 , 2025 Dear Stockholders: We are pleased to invite you to attend the 2025 Special Meeting of Stockholders (the “Special Meeting”) of CERo Therapeutics Holdings, Inc. (the “Company” or “CERo”), which will be held atPacific Time, on, 2025. The Special Meeting will be held in virtual meeting format only. You may attend the Special Meeting, submit questions and vote your shares electronically during the Special Meeting by visiting: https://www.cstproxy.com/cero/sm2025. Details regarding the business to be conducted at the Special Meeting are more fully described in the accompanying proxy statement for the Special Meeting (the “proxy statement”). Other than the